MRUS Merus N.V. Stock Quote

MRUS [NASD]

Healthcare | Biotechnology | Netherlands

Index	-	P/E	-	EPS (ttm)	-1.88	Insider Own	8.57%	Shs Outstand	43.49M	Perf Week	8.97%
Market Cap	1.04B	Forward P/E	-	EPS next Y	-2.77	Insider Trans	-1.57%	Shs Float	39.82M	Perf Month	12.62%
Income	-75.60M	PEG	-	EPS next Q	-0.60	Inst Own	78.20%	Short Float	9.90%	Perf Quarter	-15.83%
Sales	52.40M	P/S	19.86	EPS this Y	40.80%	Inst Trans	0.66%	Short Ratio	10.30	Perf Half Y	-23.78%
Book/sh	6.84	P/B	3.44	EPS next Y	-10.80%	ROA	-18.80%	Target Price	41.44	Perf Year	14.48%
Cash/sh	8.12	P/C	2.90	EPS next 5Y	-	ROE	-29.10%	52W Range	13.47 - 33.09	Perf YTD	-25.91%
Dividend	-	P/FCF	-	EPS past 5Y	13.60%	ROI	-28.50%	52W High	-27.77%	Beta	0.93
Dividend %	-	Quick Ratio	6.20	Sales past 5Y	81.30%	Gross Margin	-	52W Low	77.50%	ATR	1.59
Employees	121	Current Ratio	6.20	Sales Q/Q	39.30%	Oper. Margin	-	RSI (14)	66.56	Volatility	6.57% 6.92%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-54.90%	Profit Margin	-	Rel Volume	1.79	Prev Close	23.56
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	382.99K	Price	23.90
Recom	1.40	SMA20	11.65%	SMA50	22.51%	SMA200	-5.05%	Volume	139,762	Change	1.44%

Feb-11-22

Initiated

BMO Capital Markets

Outperform

$45

Feb-10-22

Initiated

Needham

Buy

$45

Nov-17-21

Resumed

Guggenheim

Buy

$44

Jun-07-21

Upgrade

Citigroup

Neutral → Buy

$24 → $31

Apr-08-21

Initiated

William Blair

Outperform

Mar-16-21

Initiated

SVB Leerink

Outperform

$33

Jun-26-20

Initiated

H.C. Wainwright

Buy

$23

May-27-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$16

Nov-20-19

Resumed

Guggenheim

Buy

Jun-28-19

Initiated

ROTH Capital

Buy

$20

Apr-12-19

Resumed

Guggenheim

Buy

Apr-03-19

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

Mar-27-19

Initiated

Berenberg

Buy

$35

Jan-02-18

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$28

Mar-21-17

Downgrade

Citigroup

Buy → Neutral

Dec-22-16

Upgrade

Citigroup

Neutral → Buy

Nov-07-16

Downgrade

Citigroup

Buy → Neutral

Jun-13-16

Initiated

Wedbush

Outperform

$14

Jun-13-16

Initiated

Guggenheim

Buy

Jun-28-22 08:42AM	Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business Simply Wall St.
Jun-06-22 02:54PM	Needham Says Merus' ASCO Update On Zeno 'Positive' Benzinga
Jun-05-22 11:00AM	Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract) GlobeNewswire
Jun-03-22 09:55AM	Does Merus N.V. (MRUS) Have the Potential to Rally 113% as Wall Street Analysts Expect? Zacks +11.28%
08:00AM	Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference GlobeNewswire
May-26-22 05:00PM	Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire -5.60%
09:35AM	Down 32.1% in 4 Weeks, Here's Why Merus N.V. (MRUS) Looks Ripe for a Turnaround Zacks
May-25-22 09:35AM	Merus N.V. (MRUS) Loses 30.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks
May-17-22 08:00AM	Merus to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire
May-14-22 08:00AM	Party Time: Brokers Just Made Major Increases To Their Merus N.V. (NASDAQ:MRUS) Earnings Forecasts Simply Wall St.
May-09-22 06:35PM	Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates Zacks -6.08%
04:29PM	Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update GlobeNewswire
Apr-27-22 04:01PM	Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting GlobeNewswire
Apr-25-22 08:00AM	Merus Announces Publication in Nature Cancer on Petosemtamabs (MCLA-158) Unique Mechanism of Action GlobeNewswire
Apr-08-22 01:00PM	Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022 GlobeNewswire
Apr-06-22 08:00AM	Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-18-22 09:10AM	Incyte's (INCY) Going Gets Tough Due to Pipeline Setbacks Zacks
Mar-08-22 04:35PM	Merus Announces Publication of Abstract on MCLA-129 at the American Association for Cancer Research 2022 Annual Meeting GlobeNewswire
Feb-28-22 04:37PM	Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update GlobeNewswire
Feb-03-22 08:00AM	Merus to Participate in Upcoming Investor Conferences GlobeNewswire
Jan-26-22 07:07AM	Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus Benzinga -5.06%
Jan-25-22 04:30PM	Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145 GlobeNewswire
Jan-07-22 07:19AM	We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn Simply Wall St.
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-10-21 12:36PM	Merus Shares Updated Data From Zeno Triplet Combo Data In Breast Cancer Settings Benzinga
08:00AM	Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium GlobeNewswire
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-06-21 06:42AM	Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021 GlobeNewswire
Dec-02-21 08:00AM	Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021 GlobeNewswire
Nov-10-21 08:00AM	Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual) GlobeNewswire
Nov-08-21 10:27AM	Could The Merus N.V. (NASDAQ:MRUS) Ownership Structure Tell Us Something Useful? Simply Wall St. -7.17%
Nov-04-21 09:02PM	Merus Announces Pricing of Public Offering of Common Shares GlobeNewswire
04:07PM	Merus N.V. Announces Proposed Public Offering of Common Shares GlobeNewswire
Nov-02-21 06:55PM	Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:20PM	Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update GlobeNewswire
Oct-28-21 03:05PM	Will Merus N.V. (MRUS) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-26-21 10:41AM	Where Do Hedge Funds Stand On Merus N.V. (MRUS)? Insider Monkey
Oct-08-21 05:14AM	Strength Seen in Merus N.V. (MRUS): Can Its 37.5% Jump Turn into More Strength? Zacks
Oct-07-21 04:05PM	Merus Stock Flirts With Breakout After Experimental Drug Shrinks All Tumors Investor's Business Daily +37.45%
12:01PM	28 Stocks Moving In Thursday's Mid-Day Session Benzinga
10:48AM	Here's Why Merus Stock Is Flying Higher Today Motley Fool
09:00AM	Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Sep-30-21 04:35PM	Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Sep-07-21 09:33AM	Those who invested in Merus (NASDAQ:MRUS) five years ago are up 173% Simply Wall St.
08:00AM	Merus to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-05-21 09:05PM	Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:00PM	Merus Announces Financial Results for the Second Quarter and Provides Business Update GlobeNewswire
Jul-29-21 03:05PM	Earnings Preview: Merus N.V. (MRUS) Q2 Earnings Expected to Decline Zacks
Jul-19-21 08:03PM	Hedge Funds Are Crazy About Merus N.V. (MRUS) Insider Monkey
Jul-09-21 05:09AM	A Look At The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS) Simply Wall St.
Jul-07-21 04:20PM	Merus to Participate in William Blair's Biotech Focus Conference 2021 GlobeNewswire -9.04%
Jun-04-21 03:37PM	Merus Reveals New Data From Zeno Program in NRG1 Fusion Cancers Benzinga
12:00PM	Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract) GlobeNewswire
May-26-21 04:01PM	Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-19-21 05:01PM	Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting GlobeNewswire
11:53AM	Merus N.V. (MRUS) Moves 13% Higher: Will This Strength Last? Zacks
May-13-21 08:00AM	Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial GlobeNewswire
May-11-21 08:00AM	Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference GlobeNewswire +6.74%
May-10-21 07:35AM	Here's Why We're Not Too Worried About Merus' (NASDAQ:MRUS) Cash Burn Situation Simply Wall St.
May-06-21 07:15PM	Merus N.V. (MRUS) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:14PM	Merus Announces Financial Results for the First Quarter and Provides Business Update GlobeNewswire
May-03-21 04:01PM	Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors GlobeNewswire +8.79%
Apr-28-21 04:01PM	Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting GlobeNewswire
Mar-16-21 06:15PM	Merus N.V. (MRUS) Reports Q4 Loss, Tops Revenue Estimates Zacks +5.90%
04:57PM	Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update GlobeNewswire
Mar-10-21 04:45PM	Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting GlobeNewswire +5.29%
Mar-08-21 08:00AM	Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference GlobeNewswire
Mar-04-21 12:30PM	Merus N.V. (MRUS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks -6.88%
Feb-01-21 08:00AM	Merus to Participate in Upcoming Investor Conferences GlobeNewswire
Jan-22-21 08:27AM	Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal Zacks
Jan-21-21 08:41AM	Merus Announces Pricing of Public Offering of Common Shares GlobeNewswire +8.75%
Jan-20-21 07:35AM	Lilly signs cancer drug deal worth up to $1.6 billion MarketWatch
07:32AM	The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga
05:48AM	Lilly (LLY) Inks Deal With Merus to Discover Cancer Antibodies Zacks
Jan-19-21 04:18PM	Merus N.V. Announces Proposed Public Offering of Common Shares GlobeNewswire +6.01%
06:30AM	Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies PR Newswire
Jan-12-21 04:01PM	Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial GlobeNewswire +20.30%
Jan-11-21 05:10PM	Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium GlobeNewswire
10:29AM	Company News for Jan 11, 2021 Zacks
10:04AM	Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab Zacks
Jan-07-21 04:05PM	Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers GlobeNewswire
Dec-17-20 08:00AM	Merus and Sema4 Enter Into an Agreement to Support Merus Phase 1/2 Clinical Trial of Zenocutuzumab GlobeNewswire
Dec-14-20 10:47AM	Is MRUS A Good Stock To Buy Now? Insider Monkey
Nov-16-20 08:00AM	Merus to Present at the Jefferies Virtual London Healthcare Conference GlobeNewswire
Nov-09-20 08:00AM	Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer GlobeNewswire
Nov-05-20 04:10PM	Merus Announces Financial Results for the Third Quarter and Provides Business Update GlobeNewswire
Oct-12-20 05:00PM	Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors GlobeNewswire
Sep-16-20 10:03AM	Merus (MRUS) Looks Good: Stock Adds 7% in Session Zacks
Aug-24-20 02:33PM	Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth? Simply Wall St. -6.09%
Aug-07-20 08:30AM	Merus to Present at the 2020 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-06-20 04:07PM	Merus Announces Financial Results for the Second Quarter and Provides Business Update GlobeNewswire
Jul-27-20 08:00AM	Merus Appoints Andrew Joe, M.D., as Chief Medical Officer GlobeNewswire
08:00AM	Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer GlobeNewswire
Jul-13-20 04:01PM	Merus and Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer Patients GlobeNewswire -5.01%
Jul-05-20 04:57PM	Here is What Hedge Funds Think About Merus N.V. (MRUS) Insider Monkey
Jun-12-20 11:42AM	Largest Insider Trades of the Week GuruFocus.com
Jun-05-20 11:47AM	Insiders Roundup: Avid Technology, Nebula GuruFocus.com -7.74%
Jun-01-20 04:05PM	Merus to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference GlobeNewswire

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shuman Harry	VP Controller, PAO	Jun 01	Option Exercise	0.00	2,500	0	2,500	Jun 03 04:00 PM
Shuman Harry	VP Controller, PAO	Jun 01	Sale	18.31	575	10,528	1,925	Jun 03 04:00 PM
Silverman Peter B.	EVP, GC and Head of Utrecht	Mar 10	Option Exercise	11.16	60,000	669,600	60,000	Mar 11 02:34 PM
Silverman Peter B.	EVP, GC and Head of Utrecht	Mar 10	Sale	26.95	60,000	1,617,000	0	Mar 11 02:34 PM
BVF PARTNERS L P/IL	10% Owner	Oct 08	Sale	27.79	147,267	4,092,034	232,747	Oct 08 09:24 PM
BVF PARTNERS L P/IL	10% Owner	Oct 07	Sale	27.53	985,447	27,130,440	241,676	Oct 08 09:24 PM
de Kruif John	SVP & Chief Technology Officer	Aug 12	Sale	19.34	2,787	53,901	15,282	Aug 16 09:24 AM
Lundberg Sven Ante	President, CEO & PFO	Aug 02	Option Exercise	13.36	15,000	200,474	15,000	Aug 04 03:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience